TABLE 5

Treatment outcomes stratified by susceptibility to fluoroquinolones and pyrazinamide, from individual patient data meta-analyses

Resistance profileStudiesSuccess/totalMethod of poolingSuccess versus fail/relapse
FQ-S, PZA-S3121/121Simple#100 (97–100)
FQ-S, PZA-R388/96RE92 (24–100)
FQ-R, PZA-S212/14FE86 (54–97)
FQ-R, PZA-R+119/26NA73 (52–87)

Data are presented as n, n/n or % (95% CI), unless otherwise stated. Excludes death and loss to follow-up. FQ: fluoroquinolone; PZA: pyrazinamide; R: resistant; S: susceptible; RE: random-effects meta-analysis; FE: fixed-effects meta-analysis; NA: not applicable because only one study; MIC: minimum inhibitory concentration. #: percent calculated as 100×unweighted proportion; : the FQ-R group is comprised of one participant from the Swaziland cohort with the remaining participants from the Bangladesh cohort; +: all data from the Bangladesh cohort. In a study by Aung et al. [7] reporting results from the same Bangladesh cohort, high-level gatifloxacin resistance (defined as MIC ≥2 mg·L−1) was associated with unsuccessful treatment, but not low-level gatifloxacin resistance. In the table, among persons with ofloxacin-resistant multidrug-resistant tuberculosis, high-level gatifloxacin resistance was documented in n=15, low-level gatifloxacin resistance in n=13 and gatifloxacin MIC was not measured in n=4.